Amplia has released new data which demonstrates the potential of AMP886 in the treatment of acute myeloid leukemia (AML) - a group of cancers affecting blood and bone marrow. Each year, approximately 900 Australians are diagnosed with AML, including around 50 children.
The study found that AMP886 potently inhibits AML in a well-established disease model, and when combined with venetoclax (an approved part of combination therapy), AMP886 is more effective in reducing AML cell growth than venetoclax alone.
Amplia’s CEO, Dr John Lambert commented:
“The impressive results we are reporting today tell us that there may be a clinical rationale to include AMP886 as part of new treatment regimens for unmet needs in AML. With an eye to expanding Amplia’s clinical development pipeline, further experiments are already underway with AMP886 to build on this data and establish a scientifically solid foundation for initiation of formal development of AMP886.”
Click here to read today’s ASX release.
